3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Status
Completed
3
Terminated
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Gastrointestinal
2
Conditions
Stomach Neoplasms
2
Small Cell Lung Carcinoma
1
Pleural Effusion, Malignant
1
MET Positive
1
Lung Neoplasms
1
Interventions
Capecitabine
27
pembrolizumab
19
Oxaliplatin
19
Fluorouracil
17
Cisplatin
17
Trastuzumab
14
Docetaxel
14
Leucovorin
11
Paclitaxel
8
Irinotecan
8
S 1 (combination)
7
Epirubicin
6
Cyclophosphamide
5
tegafur-gimeracil-oteracil
4
aldesleukin
4
Hyperthermic Intraperitoneal Chemotherapy
4
titanium silicide
3
spartalizumab
3
fludarabine phosphate
3
fludarabine
3
Surveys and Questionnaires
3
Surgical Procedures, Operative
3
Ramucirumab
3
Nivolumab
3
Indocyanine Green
3
Gemcitabine
3
Carboplatin
3
Albumin-Bound Paclitaxel
3
Ado-Trastuzumab Emtansine
3
vistusertib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Terminated
×
Stomach Neoplasms
×
rilotumumab
×
Clear all
NCT02137343
2016-04-04
RILOMET-2
Amgen
Phase 3
Terminated
34 enrolled
NCT01697072
2016-02-09
RILOMET-1
Amgen
Phase 3
Terminated
609 enrolled